The role of inflammation in prostate cancer

Advances in Experimental Medicine and Biology

Volumn 816, Issue , 2014, Pages 153-181

  Sfanos, Karen S ^a   Hempel, Heidi A ^a   De Marzo, Angelo M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; CANCER PREVENTION; CANCER RISK; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; CANCER GROWTH; CANCER INCIDENCE; CARCINOGENESIS; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; HEREDITY; IMMUNE RESPONSE; PREVALENCE; UNITED STATES;

ANIMALS; HUMANS; IMMUNITY, INNATE; LYMPHOCYTES; MACROPHAGES; MALE; MAST CELLS; PROSTATIC NEOPLASMS; PROSTATITIS; RISK FACTORS;

EID: 84934439509     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-348-837-8_7     Document Type: Article

References (187)

1. Aaltomaa S, Lipponen P, Papinaho S, Kosma V (1993) Mast cells in breast cancer. Anticancer Res 13(3):785-788
2. Allavena P, Sica A, Garlanda C, Mantovani A (2008) The Yin-Yang o f tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 222(1):155-161. doi:10.1111/j.1600-065X.2008.00607.x
3. Ammirante M, Luo J-L, Grivennikov S, Nedospasov S, Karin M (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464:302-305. doi:10.1038/nature08782
4. Andreani V, Gatti G, Simonella L, Rivero V, Maccioni M (2007) Activation of toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res 67(21):10519-10527. doi:10.1158/0008-5472.can-07-0079
5. Arock M, Ross E, Lai-Kuen R, Averlant G, Gao Z, Abraham SN (1998) Phagocytic and tumor necrosis factor alpha response of human mast cells following exposure to gram-negative and gram-positive bacteria. Infect Immun 66(12):6030-6034
6. Barach YS, Lee JS, Zang X (2011) T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol Med 17(1):47-55. doi:http://dx. doi.org/10.1016/j.molmed.2010.09.006
7. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077):682-687. doi:http://w ww.nature.com/nature/ journal/v439/n7077/suppinfo/nature04444-S1.html
8. Bauskin AR, Brown DA, Junankar S, Rasiah KK, Eggleton S, Hunter M, Liu T, Smith D, Kuffner T, Pankhurst GJ, Johnen H, Russell P J, Barret W, Stricker PD, Grygiel JJ, Kench JG, Henshall SM, Sutherland RL, Breit SN (2005) The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res 65(6):2330-2336. doi:10.1158/0008-5472.can- 04-3827
9. Berger P, Perng D-W, Thabrew H, Compton SJ, Cairns JA, McEuen AR, Marthan R, Tunon De Lara J-M, Walls AF (2001) Tryptase and ag onists of PAR-2 induce the proliferation of human airway smooth muscle cells. J Appl Physiol 91(3):1372-1379
10. Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, Jenkins RB, Bieberich CJ, De Marzo AM (2006) Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion. Cancer Res 66(22):10683-1 0690. doi:10.1158/0008-5472.can-06-0963
11. Bissell MJ, Hines WC (2011) Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17(3):320-329. doi:http://www. nature.com /nm/journal/v17/n3/abs/nm.2328. html#supplementary-information
12. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-α superfamily. Proc Natl Acad Sci 94(21):11514-11519
13. Breit SN, Johnen H, Cook AD, Tsai VWW, Mohammad MG, Kuffner T, Zhang HP, Marquis CP, Jiang L, Lockwood G, Lee-Ng M, Husaini Y, Wu L, Hamilton JA, Brown DA (2011) The TGF-α superfamily cy tokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 29(5):187-195. doi:10.3109/08977194.2011.607137
14. Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR, Amin J, Jung K, Diamandis EP, Hampton GM, Russell PJ, Giles GG, Breit SN (2006) Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen imp roves prostate cancer diagnosis. Clin Cancer Res 12(1):89-96. doi:10.1158/1078-0432.ccr-05-1331
15. Brown DA, Lindmark F, Stattin P, Bälter K, Adami H-O, Zheng SL, Xu J, Isaacs WB, Grönb erg H, Breit SN, Wiklund FE (2009) Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res 15(21):6658-6664. doi:10.1158/1078-0432.ccr-08-3126
16. Cairns JA, Walls AF (1996) Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J Immunol 156(1):275-283
17. Chan JK, Magistris A, Loi zzi V, Lin F, Rutgers J, Osann K, DiSaia PJ, Samoszuk M (2005) Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer. Gynecol Oncol 99(1):20-25. doi:http://dx. doi.org/10.1016/j.ygyno.2005.05.042
18. Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4(5):336-347
19. Chen Y-C, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ (2005) Sequence variants of toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 65(24):11771-11778. doi:10.1158/0008-5472.can-05-2078
20. Chen Y-C, Giovannucci E, Kraft P, Lazarus R, Hunter DJ (2007) Association between toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer. Cancer Epidemiol Biomark Prev 16(10):1982-1989. doi:10.1158/1055-9965. epi-07-0325
21. Cheng L, Wang J, Li X, Xing Q, Du P, Su L, Wang S (2011) Interleukin-6 induces Gr-1+CD11b+ myeloid cells to suppress CD8+ T cell-mediated liver injury in mice. PLoS ONE 6(3):e17631. doi:10.137 1/journal.pone.0017631
22. Cheon EC, Khazaie K, Khan MW, Strouch MJ, Krantz SB, Phillips J, Blatner NR, Hix LM, Zhang M, Dennis KL, Salabat MR, Heiferman M, Grippo PJ, Munshi HG, Gounaris E, Bentrem DJ (2011) Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APC-468 mice. Cancer Res 71(5):1627-1636. doi:10.1158/0008-5472.can-10-1923
23. Cheung PK, Woolcock B, Adomat H, Sutcliffe M, Bainbridge TC, Jones EC, Webber D, Kinahan T, Sadar M, Gleave ME, Vielkind J (2004) Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesi s. Cancer Res 64(17):5929-5933. doi:10.1158/0008-5472. can-04-1216
24. Chin AI, Miyahira AK, Covarrubias A, Teague J, Guo B, Dempsey PW, Cheng G (2010) Toll-like receptor 3-mediated suppress ion of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 70(7):2595-2603. doi:10.1158/0008-5472.can-09-1162
25. Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung H-J, Evans CP, Gao AC (2009) Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 15(15):4815-4822. doi:10.1158/1078-0432.ccr-09-0640
26. Cleme nte CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7):1303-1310 . doi:10.1002/(sici)1097-0142(19960401)77:73.3.co;2-0
27. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13(11):1382-1397
28. Crivellato E, Nico B, Mallardi F, Beltrami CA, Ribatti D (2003) Piecemeal degranulation as a gene ral secretory mechanism? Anat Rec Part A Discov Mol Cell Evol Biol 274A(1):778-784. doi:10.1002/ar.a.10095
29. Dabiri S Huntsman D Makretsov N Cheang M Gilks B Bajdik C Gelmon K Chia S Ha yes M 2004 The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis Mod Pathol 17 8 1025
30. De Marzo AM (2007) The pathology of human prostatic atrophy and inflammation. In: Chung LK, Isaacs W, Simons J (eds) Prostate cancer. Contemporary Cancer Research. Humana Press, pp 33-48. doi:10.1007/978-1-59745- 224-3-2
31. De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155(6):1985-1992. doi:http://dx.doi.org/10.1016/S0002-9440(10) 65517-4
32. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7(4):256-269
33. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G, Jumbelic M, Haas GP (2008) Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 179(5):1736-1740. doi:http://dx. doi.org/10.1016/j.juro.2008.01.034
34. Disis ML (2010) Immune regulation of cancer. J Clin Oncol 28(29):4531-4538. doi:10.1200/jco.2009.27.2146
35. Dotti G (2009) Blocking PD-1 in cancer immunotherapy. Blood 114(8):1457-1458. doi:10.1182/blood-2009-05-223412
36. Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJA, Hobo W, Gorecka MA, de Haan AFJ, Mulders P, Punt CJA, Jacobs JFM, Schalken JA, Oosterwijk E, van Eenennaam H, Boots AM (2012) PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in per ipheral blood from patients with prostate and advanced melanoma cancer. J Immunother 35(2):169-178 110.1097/CJI.1090b1013e318247a318244e318247
37. Ebelt K, Babaryka G, Frankenberger B, Stief CG, Eisenmenger W, Kirchner T, Schendel DJ, Noessner E (2009) Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer 45(9):1664-1672. doi:http://dx.doi.org/10.1016/j.ejca.2009.02.015
38. Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A , Oldenborg P-A, Palmqvist R (2012) The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of color ectal cancer. PLoS ONE 7(10):e47045. doi:10.1371/journal.pone.0047045
39. Ellem SJ, Wang H, Poutanen M, Risbridger GP (2009) Increased endogenous estrogen synthesis leads to the sequential inducti on of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am J Pathol 175(3):1187-1199. doi:http://dx.doi.org/10.2353/ajpath.2009.081107
40. Fisher E, Sass R, Watkins G, Johal J, Fisher B (1985) Tissue mast cells in breast cancer. Breast Cancer Res Treat 5(3):285-291. doi:10.1007/bf01806023
41. Fisher ER, Paik SM, Rockette H, Jones J, Caplan R, Fisher B (1989) P rognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). Human Pathol 20(2):159-163. doi:http://dx.doi. org/10.1016/0046-8177(89)90180-9
42. Flammiger A, Bayer F, Cirugeda-Kühnert A, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, Trepel M (2012) Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS 120(11):901-908. doi:10.1111/j.1600-0463.2012.02924.x
43. Fleischmann A, Schlomm T, K öllermann J, Sekulic N, Huland H, Mirlacher M, Sauter G, Sim on R, Erbersdobler A (2009) Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate 69(9):976-981. doi:10.1002/pro s.20948
44. Forssell J, O berg A, Henriksson ML, Stenling R, Jung A, Palmqvist R (2007) High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 13(5):1472-1479. doi:10.1158/1078-0432.ccr-06-2073
45. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192 (7):1027-1034. doi:10.1084/jem.192.7.1027
46. Frungieri MB, Weidinger S, Meineke V, Köhn FM, Mayerhofer A (2002) Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandin s, and PPAR?: possible relevance to human fibrotic disorders. Proc Natl Acad Sci 99(23):15072-15077. doi:10.1073/pnas.232422999
47. Fujita K, Hosomi M, Tanigawa G, Okumi M, Fushimi H, Yamaguchi S ( 2011) Prostatic inflammation detected in initial biopsy specimens and urinary pyuria are predictors of negative repeat prostate biopsy. J Urol 185(5):1722-1727. doi:http://dx.doi.org/10.1016/j.juro.2010.12.058
48. Galinsky DST, Nechushtan H (2008) Mast cells and cancer-no longer just basic science. Crit Rev Oncol/Hematol 68(2):115-130. doi:http://dx.doi.org/10. 1016/j.critrevonc.2008.06.001
49. Galli SJ (2000i Mast cells and basophils Curr Opin Hematol 7 1 32-39
50. Galli R, Starace D, Busa R, Angelini DF, Paone A, De Cesaris P, Filippini A, Sette C, Battistini L, Ziparo E, Riccioli A (2010) TLR stimulation of prostate tumor cells induces chemokinemediated recruitment of specific immune cell types. J Immunol 184(12):6658-6669. doi:10. 4049/jimmunol.0902401
51. Gocheva V, Wang H-W, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T, Joyce JA (2010) IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 24(3):241-255. doi:10.1101/gad.1874010
52. Gonzalez-Reyes S, Fernandez J, Gonzalez L, Aguirre A, Suarez A, Gonzalez J, Escaff S, Vizoso F (2011) Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their asso ciation with biochemical recurrence. Cancer Immunol Immunother 60(2):217-226
53. Gooch JL, Lee AV, Yee D (1998) Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res 58(18):4199-4205
54. Gordon JR, Galli SJ (1990) Mast cells as a source of both preformed and immunologically inducible TNF-[alpha]/cachectin. Nature 346(6281):274-276
55. Gordon J, Burd P, Galli S (1990) Mast cells as a source of multifunctional cytokines. Immunol Today 11(12):458-464
56. Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, Gounari F, Lee DM, Zhang G, Glickman JN, Shin K, Rao VP, Poutahidis T, Weissleder R, McNagny KM, Khazaie K (2007) Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci 104(5 0):19977-19982. doi:10.1073/pnas. 0704620104
57. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu G-Y, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G, Karin M (2012) Adenomalinked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491(7423):254-258. doi:http://www.natu re.com/nature/journal/v491/n7423/abs/nature11465. html#supplementary-information
58. Gruber BL, Kew RR, Jelaska A, Marchese MJ, Garlick J, Ren S, Schwartz LB, Korn JH (1997) Human mast cells activate fibroblas ts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J Immunol 158(5):2310-2317
59. Gui-zhong LI, Libo M, Guanglin H, Jianwei W (2011) Th e correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis. Int Urol Nephrol 43(2):295-301. doi:10.1007/s11255-010-9825-5
60. Gurish MF, Pear WS, Stevens RL, Sc ott ML, Sokol K, Ghildyal N, Webster MJ, Hu X, Austen KF, Baltimore D, Friend DS (1995) Tissue-regulated differentiation and maturation of a v-abl-immortalized mast cell-committed progenitor. Immunity 3( 2):175-186
61. Hagemann T, Balkwill F, Lawrence T (2007) Inflammation and cancer: a double-edged sword. Cancer Cell 12(4):300-301. doi:http://dx.doi.org/10.1016/j. ccr.2007.10.005
62. Hanahan D, Weinberg Robert A (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674. doi:http://dx.doi.org/10.1016/j.cell.2011.02. 013
63. Hao N-B, Lü M-H, Fan Y-H, Cao Y-L, Zhang Z-R, Yang S-M (2012) Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012:11. doi:10.1155/2012/948098
64. Harashima N, Inao T, Imamura R, Okano S, Suda T , Harada M (2012) Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother 61(5):667-676. doi:10.1007/s00262-011-1132-1
65. Herroon MK, Rajagurubandara E, Rudy DL, Chalasani A, Hardaway AL, Podgorski I (2013) Macrophage cathepsin K promotes prostate tumor progression in bone. Oncogene 32(12):1580-1593. doi:http://www.nature.com/onc/j ournal/v32/n12/suppinfo/onc2012166s1.html
66. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G, Klocker H, Culig Z (2000) Immunohistochemical localization of interleukin-6 and its receptor in benign, premal ignant and malignant prostate tissue. J Pathol 191(3):239-244. doi:10.1002/1096-9896(2000)9999:99993.0.co;2-x
67. Hood BL, Darfler MM, Guiel TG, Furusato B, Lucas DA, Ringeisen BR, Sesterhenn IA, Conrads TP, Veenstra TD, Krizman DB (2005) Proteomic analysis of formalin-fixed prostate cancer tissue. Mol Cell Proteomics 4(11):1741-1753. doi:10.1074/mcp.M500102-MCP200
68. Ho rner M, Ries L, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, E BK (2009) SEER Cancer Statistics Rev i ew, 1975-2006. National Cancer Institute, Bethesda, MD
69. Iamaroon A, Pongsiriwet S, Jittidecharaks S, Pattanaporn K, Prapayasatok S, Wanachantararak S (2003) Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma. J Oral Path ol Med 32(4):195-199. doi:10.1034/j.1600-0714.2003.00128.x
70. Iliopoulos D, Hirsch HA, Wang G, Struhl K (2011) Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci 108(4):1397-1402. doi:10.1073/pnas.1018898108
71. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB (1986) Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci 83(12):4464-4468
72. Irani J, Goujon J-M, Ragni E, Peyrat L, Hubert J, Saint F, Mottet N (1999) High-grade inflammation in p rostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urology 54(3):467-472. doi:http://dx.doi.org/10.1016/S0090-4295(99)00152-1
73. Johansson A, Rudolfsson S, Hammarst en P, Halin S, Pietras K, Jones J, Stattin P, Egevad L, Granfors T, Wikströ m P, Bergh A (2010) Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 177(2):1031-1041. doi:http://dx.doi.org/10.2353/ajpath. 2010.100070
74. Kaler P, Godasi B, Augenlicht L, Klampfer L (2009) The NF-kappaB/AKT-dependent Induction of Wnt signaling in colon cancer cells by macr ophages and IL-1beta. Cancer Microenviron Kang J-C, Chen J-S, Lee C-H, Chang J-J, Shieh Y-S (2010) Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. J Surg Oncol 102(3):242-248. doi:10.1002/js o.21617
75. Karan D, Holzbeierlein J, Thrasher JB (2009) Macrophage inhibitory cytokine-1: possible bridge molecule of inflammation and prostate cancer. Cancer Res 69(1):2-5. doi:10.1158/0008-5472.can-08-1230
76. Karja V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, Mokka R (2005) Tumour-infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 25(6C):4435-4438
77. Kazma R, Mefford JA, Cheng I, Plummer SJ, Levin AM, Rybicki BA, Casey G, Witte JS (2012) Association of the innate immunity a nd inflammation pathway with advanced prostate cancer risk. PLoS ONE 7(12):e51680. doi:10.1371/journal. pone.0051680
78. Kennedy R, Celis E (2008) Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 222(1):129-144. doi:10.1111/j.1600-065X.2008. 00616.x
79. Khazaie K, Blatner N, Khan M, Gounari F, Gounaris E, Dennis K, Bonertz A, Tsai F, Strouch M, Cheon E, Phillips J, Beckhove P, Bentrem D (2011) The significant role of mast cells in cancer. Cancer Metastasis Rev 30(1):45-60
80. Kim H, Bae J, Chang I, Kim K, Lee J, Shin H, Lee J, Kim W-J, Kim W, Myung S (2012) Sequence variants of toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean men. World J Urol 30(2):225-232. doi:10.1007/s00345- 011-0690-3
81. Kimura A, Kishi moto T (2010) IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40(7):1830-1835. doi:10.1002/eji.201040391
82. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, Thompson TC, Old LJ, Wang R-F (2007) CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13(23):6947-6958. doi:10.1158/1078-0432. ccr-07-0842
83. Krieger J, Nyberg L, Nickel J (1999) NIH consensus definition and classification of prostatitis. JAMA 282(3):236-237. doi:10-1001/pubs.JAMA-ISSN- 0098-7484-282-3-jac90006
84. Krishnaswamy G, Kelley J, Johnson D, Youngber g G, Stone W, Huang S, Bieber J, Chi D (2001) The human mast cell: functions in physiology and disease. Front Biosci 6:D1109-D1127
85. LaBarge MA, Nelson CM, Villadsen R, Fridriksdottir A, Ruth JR, Stampfer MR, Petersen OW, Bissell MJ (2009) Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvir onments. Integr Biol 1(1):70-79
86. Lacy P, Stow JL (2011) Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. Blood 118(1):9-18. doi:10.1182/blood-2010-08-265892
87. Leavy O (2010) Regulatory T cells: CD8+ TReg cells join the fold. Nat Rev Immunol 10(10):680-681
88. Lee Y-M, Jippo T, Kim D-K, Katsu Y, Tsujino K, Morii E, Kim H-M, Adachi S, Nawa Y, Kitamura Y (1998) Alteration of protease expression phenotype of mouse peritoneal mast cells by changing the microenvironment as demonstrated by in situ hybridization histochemistry. Am J Pathol 153 (3):931-936. doi:http://dx.doi.org/10.1016/S0002-9440(10)65634-9
89. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC (2003) Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 9(1):370-376
90. Levi-Schaffer F, Piliponsky AM (2003) Tryptase, a novel link between allergic inflammation and fibrosis. Trends Immunol 24(4):158-161. doi:http://dx.doi.org/10.1016/S1471-4906(03)00058-9
91. Li Y-W, Qiu S-J, Fan J, Gao Q, Zhou J, Xiao Y-S, Xu Y, Wang X-Y, Sun J, Huang X-W (2009a ) Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection. J Cancer Res Clin Oncol 135(3):439-449. doi:10.1007/s00432-008-0469-0
92. Li Y-Y, Hsieh L-L, T ang R-P, Liao S-K, Yeh K-Y (2009b ) Interleukin-6 (IL-6) released by macrophages induces IL-6 secretion in the human colon cancer HT-29 cell line. Hum Immunol 70(3):151-158. doi:http://dx.doi.org/10.1016/j. humimm.2009.01.004
93. Lindahl C Simonsson M Bergh A Thysell E Antti H Sund M Wikstrom P 2009Increased levels of macrophage-secreted cathepsin S during prostate cancer progression in TRAMP mice and patients Cancer Genomics Proteomics 6 3 149-159
94. Lissbrant I, Stattin P, Wikstrom P, Damber J, Egevad L, Bergh A (2000) Tumor associated macrophages in human prostate cancer: relation to clinicopath ological variables and survival. Int J Oncol 17(3):445-451
95. Liu T, Bauskin AR, Zaunders J, Brown DA, Pankurst S, Russell PJ, Breit SN (2003) Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 63(16):5034-5040
96. Liu S, Lachapelle J, Leung S, Gao D, Foulkes W, Nielsen T (2012) CD8+ lymphocyte infiltration is an indepen dent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 14(2):R48
97. Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, Pienta KJ (2006) C CL2 (Monocyte chemoattractant protein-1) is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8(7):578-586
98. Lucia M, Lambert J, Platz EA, De Marzo AM (2010) Inflammation as a target in prostate cancer. In: Figg WD, Chau CH, Small EJ (eds) Drug management of prostate cancer. Springer, New York, NY, pp 375-386
99. Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, Moser PL, Fuchs D, Hobisch A, Culig Z (2009) Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 16(1):1 55-169. doi:10.1677/erc-08-0174
100. Maltby S, Khazaie K, McNagny KM (2009) Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochimica et Biophysica Acta (BBA) Rev Cancer 1796(1):19-26. doi:http://dx.doi.org/10.1016/j.bbcan. 2009.02.001
101. Martin F, Apetoh L, Ghiringhelli F (2012) Controversies on the role of Th17 in cancer: a TGF-α-dependent immunosuppressive activity? Trends Mol Med 18(12):742-749
102. McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA (2004) The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 91(3):541-543
103. Miller AM, Lundberg K, O zenci V, Banham AH, Hellström M, Egevad L, Pisa P (2006) CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177(10):7398-7405
104. Mizutani K, Sud S, McGregor N, Martinovski G, Rice B, Craig M, Varsos Z, Roca H, Pienta K (2009) The chemokine CCL2 increases prostate tumor growth a nd bone metastasis through macrophage and osteoclast recruitment. Neoplasia 11(11):1235-1242
105. Molin D (2004) Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis. Ups J Med Sci 109(3):179-228
106. Molin D, Edströ m A, Glimelius I, Glimelius B, Nilsson G, Sundströ m C, Enblad G (2002) Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol 119(1):122-124. doi:10.1046/j.1365-2141.2002.03768.x
107. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC (2010) Regulatory T cells in cancer. In: George FVW, George K (eds) Advances in cancer research, vol 107. Academic Press, pp 57-117. doi:http://dx.doi.org/10. 1016/S0065-230X(10)07003-X
108. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer . Cancer Res 58(16):3491-3494
109. Nakamura T, Scorilas A, Stephan C, Yousef GM, Kristiansen G, Jung K, Diamandis EP (2003) Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer 88(7):1101-1104
110. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, De Marzo AM (2003) Hypermethylation of the hum an glutathione S-transferase-γ gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Patho l 163(3):923-933. doi:http://dx.doi.org/10.1016/S0002-9440(10)63452-9
111. Nakayama T, Yao L, Tosato G (2004) Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin Investig 114(9):1317-1325. doi:10.1172/jci22089
112. Nelson WG, De Marzo AM, Isaacs WB (2003) Prostate cancer. N Engl J Med 349(4):366-381. doi:10.1056/NEJMra021562
113. Nelson W, Sfanos K, DeMarzo A, Yegnasubramanian S (2013) Prostate inflammation and prostate cancer. In: Klein EA, Jones JS (eds) Management of prostate cancer, current clinical urology. Humana Press, New York, NY, pp 103-115
114. Nickel JC Downey J Young I Boag S 1999 Asymptomatic inflammation and/or infection in benign prostatic hyperplasia BJU International 84 9 976-981 doi:10.1046/j.1464-410x.19 99.00352.x
115. Nonomura N, Takayama H, Nishimura K, Oka D, Nakai Y, Shiba M, Tsujimura A, Nakayama M, Aozasa K, Okuyama A (2007) Decreased number of mast cells infiltrating into needle biopsy specime ns leads to a better prognosis of prostate cancer. Br J Cancer 97(7):952-956
116. Nonomura N, Takayama H, Nakayama M, Nakai Y, Kawashima A, Mukai M, Nagahara A, Aozasa K, Tsujimura A (2011) Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int 107(12):1918-1922. doi:10.1111/j.1464-410X.2010.09804.x
117. Okamoto M, Lee C, Oyasu R (1997) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57(1):141-146
118. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182(8):4499-4506. doi:10.4049/jimmunol.0802740
119. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG (2005) Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26(7):1170-1181. doi: 10.1093/carcin/bgh317
120. Paone A, Starace D, Galli R, Padula F, De Cesaris P, Filippini A, Ziparo E, Riccioli A (2008) Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-α-dependent mechanism. Carcinogenesis 29(7):1334-1342. doi:10.1093/carcin/bgn149
121. Pardoll D (2002) T cells take aim at cancer. Proc Natl Acad Sci 99(25):15840-15842. doi:10.107 3/pnas.262669499
122. Pittoni P, Colombo MP (2012) The dark side of mast cell-targeted therapy in prostate cancer. Cancer Res 72(4):831-835. doi:10.1158/0008-5472.can-11-3110
123. Pittoni P, Tripod o C, Piconese S, Mauri G, Parenza M, Rigoni A, Sangaletti S, Colombo MP (2011) Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res. doi:10.1158/0008-5472.can-11-1637
124. Platz EA, De Marzo AM, Erlinger TP, Rifai N, Visvanathan K, Hoffman SC, Helzlsouer KJ (2004) No association between pre-diagnostic plasma C-reactive protein concentrati on and subsequent prostate cancer. Prostate 59(4):393-400. doi:10.1002/pros.10368
125. Ports MO, Nagle RB, Pond GD, Cress AE (2009) Extracellular engagement of α6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res 69(12):5007-5014. doi:10.1158/0008-5472.can-09-0354
126. Powell IJ, Dyson G, Land S, Ruterbusch J, Bock CH, Lenk S, Herawi M, Everson RB, Giroux CN, Schwartz AG, Bollig-Fischer A (2013) Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomark Pr ev. doi:10.1158/1055-9965. epi-12-1238
127. Proctor MJ, Talwar D, Balmar SM, O'Reilly DSJ, Foulis AK, Horgan PG, Morrison DS, McMillan DC (2010) The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow inflammation outcome study. Br J Cancer 103(6):870-876
128. Punturieri A, Filippov S, Allen E, Caras I, Murray R, Reddy V, Weiss SJ (2000) Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp Med 192(6):789-800. doi:10.1084/jem.192.6.789
129. Putzi MJ, De Marzo AM (2000) Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 56(5):828-832. doi:http://dx.doi.org/10.1016/S0090-4295(00) 00776-7
130. Rajput A, Turbin D, Cheang M, Voduc D, Leung S, Gelmon K, Gilks CB, Huntsman D (2008) Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res T reat 107(2):249-257. doi:10.1007/s10549-007-9546-3
131. Rakoff-Nahoum S, Medzhitov R (2009) Toll-like receptors and cancer. Nat Rev Cancer 9(1):57-63
132. Rao UNM, Lee SJ, Luo W, Mihm MC, Kirkwood JM (2010) Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (T4) primary melanoma: pathologic analy sis of the E1690 and E1694 intergroup trials. Am J Clin Pathol 133(4):646-653. doi:10.1309/ajcp txmefovywda6
133. Rasiah KK, Kench JG, Gardiner-Garden M, Biankin AV, Golovsky D, Brenner PC, Kooner R, O'Neill GF, Turner JJ, Delprado W, Lee CS, Brown DA, Breit SN, Grygiel JJ, Horvath LG, Stricker PD, Sutherland RL, Henshall SM (2006) Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol Biomark Prev 15(4):711-716. doi:10.1158/1055-9965.epi-05-0752
134. Reams RR, Agrawal D, Davis M, Yoder S, Odedina F, Kumar N, Higginbotham
135. Ribatti D, Vacca A, Nico B, Quondamatteo F, Ria R, Minischetti M, Marzullo A, Herken R, Roncali L, Dammacco F (1999) Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 79(3-4):451-455
136. Ribatti D, Vacca A, Ria R, Marzullo A, Nico B, Filotico R, Roncali L, Dammacco F (2003) Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously w ith pathological progression in human malignant melanoma. Eur J Cancer 39(5):666-674. doi:http://dx.doi.org/10.1016/S0959-8049(02)00150-8
137. Ribatti D, Finato N, Crivellato E, Marzullo A, Mangieri D, Nico B, Vacca A, Beltrami CA (2005) Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer. Am J Obstet Gynecol 193(6):1961-1965. d oi:http://dx.doi.org/10.1016/j.ajog. 2005.04.055
138. Richardsen E, Uglehus RD, Due J, Busch C, Busund LTR (2008) The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma. Histopatho logy 53(1):30-38. doi:10.1111/j.1365-2559.2008.03058.x
139. Rigamonti N, Capuano G, Ricupito A, Jachetti E, Grioni M, Generoso L, Freschi M, Bellone M (2011) Modulators of arginine metabolis m do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer. Clin Cancer Res 17(5):1012-1023. doi:10.1158/1078-0432.ccr-10- 2547
140. Roca H, Varsos ZS, Sud S , Craig MJ, Ying C, Pienta KJ (2009) CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 284(49):34342-34354. do i:10.1074/jbc.M109.042671
141. Sari S, C andir O, Oztü rk K (1999) Mast cell variations in tumour tissue and with histopathological grading in specimens of prostatic adenocarcinoma. BJU Int 84(7):851-853. doi:10.1046/j.1464-410x.1999.00245.x
142. Schumacher K, Haensch W, Rö efzaad C, Schlag PM (2001) Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas. Cancer Res 61(10):3932-3936
143. Selander KS, Brown DA, Sequeiros GB, Hunter M, Desmond R, Parpala T, Risteli J, Breit SN, Jukkola-Vuorinen A (2007) Serum macrophage inhibitory cytokine-1 concentrations correlate with the pr esence of prostate cancer bone metastases. Cancer Epidemiol Biomark Prev 16(3):532-537. doi:10.1158/1055-9965. epi-06-0841
144. Sfanos KS, De Marzo AM (2012) Prostate cancer and inflammation: the evidence. Histopathology 60(1):199-215. doi:10.1111/j.1365-2559.2011.04033.x
145. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG (2008) Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 14(11):3254-3261. doi:10.1158/1078-0432.ccr-07-5164
146. Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG (2009a ) Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 69(15):1694-1703. doi:10.1002/pros.21020
147. Sfanos KS, Wilson BA, De Marzo AM, Isaacs WB (2009b ) Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proc Natl Acad Sci 106(9):3443-3448. doi:10.1073/pnas.0810473106
148. Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS (2012) Systemic inflammation and survival of patients with prostate cancer: evidence from the Glas gow inflammation outcome study. Prostate Cancer Prostatic Dis 15(2):195-201
149. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC (2000) Reduced infiltration of tumor-associated mac rophages in human prostate cancer: association with cancer progression. Cancer Res 60(20):5857-5861
150. Shui IM, Stark JR, Penney KL, Schumacher FR, Epstein MM, Pitt MJ, Stampfer MJ, Tamimi RM, Lindstrom S, Sesso HD, Fall K, Ma J, Kraft P, Giovannucci E, Mucci LA (2012) Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate 72(2):209-216. doi :10.1002/pros.21423
151. Smith PC, Hobisch A, Lin D-L, Culig Z, Keller ET (2001) Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12(1):33-40. doi:http://dx.doi.org/10.1016/S1359-6101(00)00021-6
152. Sroka IC, Sandoval CP, Chopra H, Gard JMC, Pawar SC, Cress AE (2011) Macrophagedependent cleavage of the laminin receptor α6β1 in prostate cancer. Mol Cancer Res 9(10):1319-1328. doi:10.1158/1541-7786.mcr-11-0080
153. Stimac G, Reljic A, Spajic B, Dimanovski J, Ruzic B, Ulamec M, Sonicki Z, Kraus O (2009) Aggressiveness of in flammation in histological prostatitis-correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy. Scott Med J 54(3):8-12. doi:10.1258/rsmsmj.54.3.8
154. Strou ch MJ, Cheon EC, Salabat MR, Krantz SB, Gounaris E, Melstrom LG, Dangi-Garimella S, Wang E, Munshi HG, Khazaie K, Bentrem DJ (2010) Crosstalk between mast cells and pancreatic cancer cells contributes to pancre atic tumor progression. Clin Cancer Res 16(8):2257-2265. doi:10.1158/1078-0432.ccr-09-1230
155. Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L, Johansson J-E, Li G, Adami H-O, Li u W, Tolin A, Turner AR, Meyers DA, Isaacs WB, Xu J, Grö nberg H (2005) Sequence variants in toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 97(7):525-532. doi:10.1093/jnci/dji070
156. Svensson RU, Haverkamp JM, Thedens DR, Cohen MB, Ratliff TL, Henry MD (2011) Slow disease progression in a C57BL/6 Pten-deficient mouse model of prostate cancer. Am J Pathol 1 79(1):502-512. doi:http://dx.doi.org/10.1016/j. ajpath.2011.03.014
157. Swann JB Smyth MJ 2007 Immune surveillance of tumors J Clin Investig 117 5 1137-1146 doi:10.1172/jci31405
158. Tanner J, Tosato G (1992) Regulation of B-cell growth and immunoglobulin gene transcription by interleukin-6. Blood 79(2):452-459
159. Theoharides TC, Conti P (2004) Mast cells: the JEKYLL and HYDE of tumor growth. Trends Immunol 25(5):235-241. doi:http://dx.doi.org/10.1016/j.it.2004. 02.013
160. Tuna B, Yorukoglu K, Unlu M, Mungan MU, Kirkali Z (2006) Association of mast cells with microvessel density in renal cell carcinomas. European Urol 50(3):530-534. doi:http://dx. doi.org/10.1016/j.eururo.2005.12.040
161. Turnis ME, Korman AJ, Drake CG, Vignali DAA (2012) Combinatorial immunotherapy: PD-1 may not be LAG-ing behind any more. OncoImmunology 1(7):1172-1174
162. Twillie DA, Eisenberger MA, Cardu cci MA, Hseih W-S, Kim WY, Simons JW (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45(3):542-549. doi:http://dx.doi.org/10.1016/S0090-4295(99)80034-X
163. Ugurlu O, Yaris M, Oztekin CV, Kosan TM, Adsan O, Cetinkaya M (2010) Impacts of antibiotic and anti-inflammatory therapies on serum prostate-specific antigen levels in the presence of prostatic inflammation: a prospective randomiz ed controlled trial. Urol Int 84(2):185-190. doi:10.1159/000277596
164. van Dijk M, Gö ransson SA, Strömblad S (2013) Cell to extracellular matrix interactions and their reciprocal nature in cancer. Exp Cell Res (0). doi:http://dx.doi.org/10.1016/j.yexcr.2013.02.006
165. Vasiljeva O, Papazoglou A, Kr üger A, Brodoefel H, Korovin M, Deussing J, Augustin N, Nielsen BS, Almholt K, Bogyo M, Peters C, Re inheckel T (2006) Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 66(10):5242-5250. doi:10.1158/0008-5472.can-05-4463
166. Vesalaine n S, Lipponen P, Talja M, Syrjä nen K (1994) Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. European J Cancer 30(1 2):1797-1803. doi:http://dx. doi.org/10.1016/0959-8049(94)E0159-2
167. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29(1): 235-271. doi:10.1146/annurev-immunol-031210-101324
168. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW (2013) Cancer genome landscapes. Science 339(6127):1546-1558. doi:10.1126/science.1235122
169. Vykhovanets E, Maclennan G, Vykhovanets O, Gupta S (2011) IL-17 Expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients. Int J Clin Exp Pathol 4(6):552-565
170. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S (2008) Tumor immunobiological d ifferences in prostate cancer between African-American and European-American men. Cancer Res 68(3):927-936. doi:10.1158/0008-5472.can-07-2608
171. Wang W, Bergh A, Damber J-E (2005) Cyclooxygenase-2 ex pression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11(9):3250-3256. doi:10.1158/1078-0432.ccr-04- 2405
172. Wang W, Bergh A, Damber J-E (2009) Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate 69(13):1378-1386. doi:10.1002/pros.20992
173. Welsh JB, Sap inoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Hampton GM (2001) Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61( 16):5974-5978
174. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF, Hampton G M (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci 100(6):3410-3415. doi:10.1073/pnas.0530278100
175. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P (2005) Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in nonsmall-cell lung cancer. J Clin Oncol 23(35):8959-8967. doi:10.1200/jco.2005.01.4910
176. Wiklund FE, Bennet AM, Magnusson PKE, Eriksson UK, Lindmark F, Wu L, Yaghoutyfam N, Marquis CP, Stattin P, Pedersen NL, Adami H-O, Grö nberg H, Breit SN, Brown DA (2010) Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 9(6):1057-1064. doi:10.1111/j.1474- 9726.2010.00629.x
177. Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, Zou W (2011) Th17 cells in cancer: help or hindrance? Carcinogenesis 32(5):643-649. doi:10.1093/carcin/bgr019
178. Wu C-T Hsieh C-C Lin C-C Ch en W-C Hong J-H Chen M-F 2012 Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells J Mol Med 90 11 1343-1355 doi:10.1007/s00109-012-0916-x
179. Yang G, Addai J, W-h Tian, Frolov A, Wheeler TM, Thompson TC (2004) Reduced infiltration of class A scavenger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res 64(6):2076-2082. doi:10.1158/0008-5472.can-03-4072
180. Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, Tsang KY (2008) Enhanced functionality of CD4+CD25highFox P3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 14(4):1032-1040. doi:10.1158/1078-0432.ccr-07-2056
181. Yoshii M, Jikuhara A, Mori S, Iwagaki H, Takahash i HK, Nishibori M, Tanaka N (2005) Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin-and MAP kinase-dependent manners. J Pharmacol Sci 98(4):450-458
182. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203-213. doi:10. 1056/NEJMoa020177
183. Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, Xue X, Wei G, Liu X, Fang G (2008) The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374(3):533-537. doi:http://dx.doi.org/10.1016/j.bbrc.2008.07. 060
184. Zhang Q-w, Liu L, Gong C-Y, Shi H-S, Zeng Y-H, Wang X-Z, Zhao Y-W, Wei Y-Q (2012) Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE 7(12):e50946. doi:10.1371/journal.pone.0050946
185. Zheng SL, Augustsson-Bä lter K, Chang B, Hedelin M, Li L, Adami H-O, Bensen J, Li G, Johnasson J-E, Turner AR, Adams TS, Meyers DA, Isaacs WB, Xu J, Grö nberg H (2004) Sequence variants of toll-like receptor 4 are associated w ith prostate cancer risk: results from the cancer prostate in Sweden Study. Cancer Res 64(8):2918-2922. doi:10.1158/0008-5472.can-03-3280
186. Zhou Q, Peng R-Q, Wu X-J, Xia Q, Hou J-H, Ding Y, Z hou Q-M, Zhang X, Pang Z-Z, Wan D-S, Zeng Y-X, Zhang X-S (2010) The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med 8(1):13
187. Zou W, Restifo NP (2010) TH17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10(4):248-256